Name | Number of supported studies | Average coverage | |
---|---|---|---|
smooth muscle cell | 12 studies | 26% ± 8% | |
glutamatergic neuron | 11 studies | 52% ± 25% | |
endothelial cell of lymphatic vessel | 9 studies | 31% ± 10% | |
type I pneumocyte | 8 studies | 39% ± 16% | |
type II pneumocyte | 7 studies | 39% ± 17% | |
retinal ganglion cell | 6 studies | 29% ± 12% | |
endothelial cell | 5 studies | 45% ± 21% | |
epithelial cell | 5 studies | 39% ± 19% | |
mesothelial cell | 5 studies | 26% ± 6% | |
GABAergic neuron | 5 studies | 55% ± 16% | |
erythrocyte | 5 studies | 32% ± 18% | |
pericyte | 5 studies | 22% ± 5% | |
fibroblast | 5 studies | 29% ± 12% | |
interneuron | 5 studies | 41% ± 24% | |
club cell | 4 studies | 25% ± 7% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 19% ± 4% | |
muscle cell | 3 studies | 25% ± 12% | |
macrophage | 3 studies | 30% ± 10% | |
monocyte | 3 studies | 25% ± 5% | |
granule cell | 3 studies | 64% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 99% | 8710.75 | 954 / 966 | 99% | 21.29 | 522 / 527 |
lung | 98% | 5952.59 | 566 / 578 | 94% | 17.83 | 1086 / 1155 |
stomach | 86% | 4422.61 | 308 / 359 | 99% | 22.69 | 283 / 286 |
bladder | 86% | 3801.90 | 18 / 21 | 87% | 13.15 | 439 / 504 |
esophagus | 68% | 7761.46 | 984 / 1445 | 97% | 20.38 | 177 / 183 |
uterus | 94% | 7806.42 | 159 / 170 | 68% | 7.35 | 314 / 459 |
prostate | 71% | 2822.10 | 174 / 245 | 88% | 10.92 | 444 / 502 |
thymus | 63% | 1783.46 | 414 / 653 | 76% | 8.41 | 457 / 605 |
breast | 34% | 940.39 | 155 / 459 | 97% | 18.33 | 1086 / 1118 |
pancreas | 34% | 893.30 | 110 / 328 | 97% | 20.72 | 173 / 178 |
ovary | 52% | 2207.03 | 94 / 180 | 78% | 8.17 | 337 / 430 |
skin | 68% | 2955.04 | 1238 / 1809 | 54% | 5.82 | 257 / 472 |
brain | 64% | 11593.64 | 1691 / 2642 | 45% | 4.52 | 314 / 705 |
blood vessel | 100% | 25842.58 | 1335 / 1335 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.56 | 1 / 1 |
liver | 35% | 941.91 | 79 / 226 | 56% | 3.93 | 229 / 406 |
adrenal gland | 59% | 1761.48 | 152 / 258 | 32% | 2.25 | 74 / 230 |
kidney | 25% | 841.82 | 22 / 89 | 65% | 5.76 | 582 / 901 |
heart | 89% | 5315.02 | 768 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 73% | 3144.03 | 681 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 67% | 6.82 | 30 / 45 |
adipose | 59% | 1895.73 | 705 / 1204 | 0% | 0 | 0 / 0 |
muscle | 57% | 2771.35 | 456 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 38% | 2.26 | 11 / 29 |
spleen | 21% | 513.93 | 50 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0019417 | Biological process | sulfur oxidation |
GO_0030042 | Biological process | actin filament depolymerization |
GO_0001947 | Biological process | heart looping |
GO_0007010 | Biological process | cytoskeleton organization |
GO_0007507 | Biological process | heart development |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005884 | Cellular component | actin filament |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0051019 | Molecular function | mitogen-activated protein kinase binding |
GO_0071949 | Molecular function | FAD binding |
GO_0016709 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen |
GO_0016491 | Molecular function | oxidoreductase activity |
GO_0004497 | Molecular function | monooxygenase activity |
GO_0016174 | Molecular function | NAD(P)H oxidase H2O2-forming activity |
GO_0005515 | Molecular function | protein binding |
GO_0003779 | Molecular function | actin binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | MICAL2 |
Protein name | Alternative protein MICAL2 [F-actin]-monooxygenase MICAL2 (EC 1.14.13.225) (MICAL C-terminal-like protein) (Mical-cL) (Molecule interacting with CasL protein 2) (MICAL-2) Microtubule associated monooxygenase, calponin and LIM domain containing 2 |
Synonyms | MICALCL KIAA0750 MICAL2PV2 MICAL2PV1 |
Description | FUNCTION: Methionine monooxygenase that promotes depolymerization of F-actin by mediating oxidation of residues 'Met-44' and 'Met-47' on actin to form methionine-sulfoxide, resulting in actin filament disassembly and preventing repolymerization . Regulates the disassembly of branched actin networks also by oxidizing ARP3B-containing ARP2/3 complexes leading to ARP3B dissociation from the network . Acts as a key regulator of the SRF signaling pathway elicited by nerve growth factor and serum: mediates oxidation and subsequent depolymerization of nuclear actin, leading to increase MKL1/MRTF-A presence in the nucleus and promote SRF:MKL1/MRTF-A-dependent gene transcription. Does not activate SRF:MKL1/MRTF-A through RhoA . . |
Accessions | ENST00000675839.1 [O94851-3] E9PNC3 E9PKI3 ENST00000524685.5 ENST00000532420.1 ENST00000683283.1 [O94851-1] A0A2R8Y771 ENST00000646065.1 [O94851-7] ENST00000707072.1 [O94851-4] E9PRG5 ENST00000528931.5 [O94851-6] O94851 ENST00000533534.2 ENST00000532179.5 L8EAP5 ENST00000526065.1 E9PJB0 E9PL42 ENST00000529028.1 E9PRE0 ENST00000525119.5 ENST00000256194.8 [O94851-1] ENST00000533389.1 ENST00000646734.1 A0A2R8Y7K9 ENST00000527546.5 [O94851-5] |